Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
Take 1 tablet of this medicine 5/1000 mg extended-release tablet once daily.
Patients taking this medicine 2.5/1000 mg extended-release tablet should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and the dose should be adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter.
No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.
Improvement of glycemic control in patients with type 2 diabetes mellitus
View approved original textHide original text
This medication is used to assist patients with type 2 diabetes in achieving more effective blood sugar control by complementing dietary and exercise therapy. It is particularly suitable for patients requiring combination therapy with linagliptin and metformin, helping to manage blood sugar levels stably. This way, it supports enhanced diabetes management and helps maintain a healthy lifestyle.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg.
This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
Take 1 tablet of this medicine 5/1000 mg extended-release tablet once daily.
Patients taking this medicine 2.5/1000 mg extended-release tablet should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and the dose should be adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter.
No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.
Precautions
This medication is used for the treatment of type 2 diabetes and helps in controlling blood sugar levels.
However, precautions must be strictly followed while taking this medication.
First, this medication can rarely cause a serious condition known as lactic acidosis, which can lead to the excessive accumulation of lactic acid in the body, posing a dangerous condition requiring immediate treatment.
Therefore, patients with moderate to severe kidney impairment, acute kidney injury, severe infections, or significant dehydration should not take this medication.
Additionally, it is safer for patients with liver dysfunction, acute alcohol intoxication, or serious heart or respiratory diseases not to use this medication.
Hypoglycemic symptoms may occur during the course of this medication, so care should be taken to monitor blood sugar changes, especially when taken with sulfonylureas or insulin.
Acute pancreatitis or blistering skin diseases may also arise, so if severe abdominal pain or skin abnormalities occur during use, immediate consultation with a physician is necessary.
This medication can lower vitamin B12 levels, so during long-term use, it is necessary to confirm vitamin B12 status through a blood test.
Swallow the tablets whole without crushing, chewing, or breaking them, and it is normal for the tablet shell to pass in the stool.
Furthermore, this medication may interact with other drugs, so if other medications are being taken, it is essential to inform your doctor or pharmacist.
Women who are pregnant or breastfeeding should avoid this medication, and those planning a pregnancy should consult a doctor.
Elderly patients may have decreased kidney function, so regular kidney function tests should be conducted, and dosage adjustments may be necessary.
Finally, in case of overdose, immediate medical attention should be sought for appropriate treatment, and prompt action is needed, especially when symptoms of lactic acidosis occur.
By adhering to these precautions and following the doctor’s instructions, the benefits of this medication can be safely enjoyed.
Side effects
Severe lactic acidosis
hypoglycemia
nasopharyngitis
hypersensitivity reactions
angioedema
urticaria
lactic acidosis
abnormal vitamin B12 absorption test
hypoglycemic syndrome
taste disturbances
Show 136 moreCollapse
cough
decreased appetite
diarrhea
constipation
nausea
pancreatitis
vomiting
abdominal pain
oral ulceration
abnormal liver function tests
hepatitis
pruritus
erythema
rash
dermatitis herpetiformis
severe and disabling arthralgia
rhabdomyolysis
increased lipase
increased amylase
constipation
upper abdominal pain
enterocolitis
bowel obstruction
gastroenteritis
herpes zoster
cystitis
acute pyelonephritis
bronchitis
vestibular neuritis
sepsis
pneumonia
decreased appetite
dehydration
hyperglycemia
cerebral infarction
stuttering
Alzheimer's type dementia
chest pain
fever
facial edema
fatigue
chronic obstructive pulmonary disease
asthma
diabetic foot disease
skin lesions
liver metastasis
acute leukemia
basal cell carcinoma
non-small cell lung cancer
malignant pericardial effusion
gastric cancer
rectal cancer
pancreatic cancer
meniscus injury
pneumoconiosis
congestive heart failure
angina
acute myocardial infarction
unstable angina
cardiac arrest
diabetic retinopathy
acute kidney injury
end-stage renal disease
acute cholangitis
acute cholecystitis
cholangitis
dizziness
renal transplant failure
anxiety
affective disorder
insomnia
depression
contusion
bone contusion
concussion
bone fracture
hand fracture
palpitations
dry eyes
glaucoma
cataract
eye discomfort
allergic conjunctivitis
polyuria
proteinuria
hematuria
hypotension
flushing
hepatic steatosis
cholelithiasis
hearing loss
erectile dysfunction
goiter
anemia
nausea
gastroesophageal reflux disease
gastritis
dizziness
sensory loss
chest discomfort
asthenia
pain
epistaxis
oropharyngeal pain
voice disorders
allergic rhinitis
exertional dyspnea
wet cough
rhinorrhea
pulmonary mass
arthralgia
osteoporosis
arthropathy
musculoskeletal discomfort
myositis
myalgia
soft tissue mass
postmenopausal osteoporosis
rotator cuff syndrome
increased serum triglycerides
increased urine albumin/creatinine ratio
positive urine leukocytes
hemoglobin reduction
increased serum potassium
increased serum creatinine
increased serum creatine kinase activity
increased ALT
increased AST
androgenetic alopecia
hyperhidrosis
dermatitis
anxiety
confusion
nocturia
dermatitis
hypertension
Not everyone experiences these, and they can vary from person to person.
Storage
This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1°C and 30°C.
Appearance and packaging
Appearance
Yellow oval extended-release film-coated tablet
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.